{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:59:15Z","timestamp":1790719155235,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European Alliance of Associations for Rheumatology","doi-asserted-by":"publisher","award":["CLI113"],"award-info":[{"award-number":["CLI113"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ero.2025.11.015","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:27:03Z","timestamp":1765456023000},"page":"100088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The EULAR points to consider regarding the development of criteria for the assessment of the disease activity in adult-onset Still\u2019s disease"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3487-8551","authenticated-orcid":false,"given":"Piero","family":"Ruscitti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Ritschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Mitrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Girard-Guyonvarc\u2019h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Alexanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Barten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Bostr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Fell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"K\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Rosine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanita-Christina","family":"Wilhelmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Gonzalez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Gabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ero.2025.11.015_bib0001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset Still's disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J Autoimmun"},{"issue":"12","key":"10.1016\/j.ero.2025.11.015_bib0002","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1136\/ard-2024-225851","article-title":"EULAR\/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease","volume":"83","author":"Fautrel","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ero.2025.11.015_bib0003","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still's disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2025.11.015_bib0004","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/art.1780300209","article-title":"Adult-onset Still's disease. Clinical course and outcome","volume":"30","author":"Cush","year":"1987","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ero.2025.11.015_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101632","article-title":"The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients","volume":"58","author":"Ruscitti","year":"2021","journal-title":"Semin Immunol"},{"issue":"5","key":"10.1016\/j.ero.2025.11.015_bib0006","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/1744666X.2018.1465821","article-title":"Complications of adult-onset Still's disease and their management","volume":"14","author":"Mitrovic","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.ero.2025.11.015_bib0007","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12916-016-0738-8","article-title":"Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers","volume":"14","author":"Ruscitti","year":"2016","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.ero.2025.11.015_bib0008","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ero.2025.11.015_bib0009","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3899\/jrheum.2023-0995","article-title":"Systematic review and meta-analysis of pharmacological interventions in adult-onset Still's disease highlights the beneficial role of biologic DMARDs","volume":"51","author":"Ruscitti","year":"2024","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.ero.2025.11.015_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103400","article-title":"Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission","volume":"22","author":"Giacomelli","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.ero.2025.11.015_bib0011","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"10.1016\/j.ero.2025.11.015_bib0012","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ero.2025.11.015_bib0013","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ero.2025.11.015_bib0014","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study","volume":"39","author":"Nordstr\u00f6m","year":"2012","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2025.11.015_bib0015","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ero.2025.11.015_bib0016","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ero.2025.11.015_bib0017","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.015_bib0018","doi-asserted-by":"crossref","unstructured":"Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum. 2002 May;46(5):1171-6. doi:10.1002\/art.10231.","DOI":"10.1002\/art.10231"},{"issue":"1","key":"10.1016\/j.ero.2025.11.015_bib0019","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","article-title":"Tocilizumab in refractory adult Still's disease","volume":"63","author":"Pu\u00e9chal","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.ero.2025.11.015_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","article-title":"Tocilizumab for the treatment of adult-onset Still's disease: results from a case series","volume":"33","author":"Cipriani","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ero.2025.11.015_bib0021","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fphar.2017.00369","article-title":"Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still's Disease: a multicentre retrospective observational study","volume":"8","author":"Colafrancesco","year":"2017","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.ero.2025.11.015_bib0022","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult Still's disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.ero.2025.11.015_bib0023","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3899\/jrheum.100247","article-title":"Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis","volume":"37","author":"Rau","year":"2010","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.ero.2025.11.015_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003419","article-title":"Derivation and validation of four patient clusters in Still's disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry","volume":"9","author":"Ruscitti","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ero.2025.11.015_bib0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.015_bib0026","unstructured":"Girard-Guyonvarc\u2019h C, Mitrovic S, Ruscitti P, Fautrel B, Gabay C, Gonzalez-Gay MA, et al. Clinical, biological, and radiological changes under therapy, and criteria of clinical response as well as remission in adult onset Still\u2019s disease: a systematic literature review \u2013 EULAR Rheumatology Open \u2013 ERO-D-25-00032 \u2013 Accepted, In Press."},{"key":"10.1016\/j.ero.2025.11.015_bib0027","unstructured":"Mitrovic S, Girard-Guyonvarc\u2019h C, Ruscitti P, Gabay C, Gonzalez-Gay MA, Feist E, et al. Items identified by expert physicians for a disease activity score for adult-onset Still\u2019s disease (the DAVID score): results of a Web-based Delphi study \u2013 EULAR Rheumatology Open \u2013 ERO-D-25-00033 \u2013 Accepted, In Press."},{"key":"10.1016\/j.ero.2025.11.015_bib0029","unstructured":"CEBM. Centre for evidence-based medicine. Available from: https:\/\/www.cebm.ox.ac.uk. Accessed November 1, 2025."},{"issue":"10","key":"10.1016\/j.ero.2025.11.015_bib0030","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/ard-2023-224123","article-title":"The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS)","volume":"82","author":"Shakoory","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ero.2025.11.015_bib0031","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.015_bib0032","doi-asserted-by":"crossref","unstructured":"Colina M, Zucchini W, Ciancio G, Orzincolo C, Trotta F, Govoni M. The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum. 2011 Oct;41(2):279-85. doi:10.1016\/j.semarthrit.2010.12.006","DOI":"10.1016\/j.semarthrit.2010.12.006"},{"issue":"1","key":"10.1016\/j.ero.2025.11.015_bib0033","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/s10165-008-0126-0","article-title":"Cyclosporin A treatment for Japanese patients with severe adult-onset Still's disease","volume":"19","author":"Mitamura","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.ero.2025.11.015_bib0034","first-page":"16634","article-title":"Clinical features and prognosis of adult-onset Still's disease: 75 cases from China","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"5","key":"10.1016\/j.ero.2025.11.015_bib0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1056\/NEJMra2111003","article-title":"Fever of unknown origin","volume":"386","author":"Haidar","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ero.2025.11.015_bib0036","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00296-011-2330-z","article-title":"Cutaneous manifestations associated with adult-onset Still's disease: important diagnostic values","volume":"32","author":"Yamamoto","year":"2012","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.ero.2025.11.015_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101942","article-title":"Pain mechanisms for the practicing rheumatologist","volume":"38","author":"Minhas","year":"2024","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.ero.2025.11.015_bib0039","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrrheum.2014.64","article-title":"Mechanisms, impact and management of pain in rheumatoid arthritis","volume":"10","author":"Walsh","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.11.015_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91613-5","article-title":"The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile","volume":"11","author":"Ruscitti","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ero.2025.11.015_bib0041","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2025.11.015_bib0042","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/rheumatology\/kead644","article-title":"Lymphadenopathy in the rheumatology practice: a pragmatic approach","volume":"63","author":"Rodolfi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ero.2025.11.015_bib0043","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/rheumatology\/kez392","article-title":"Biomarkers for disease flare in patients with adult-onset Still's disease undergoing treatment with tocilizumab","volume":"59","author":"Yamada","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"9927","key":"10.1016\/j.ero.2025.11.015_bib0044","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ero.2025.11.015_bib0045","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.21901","article-title":"Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy","volume":"65","author":"Giampietro","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.ero.2025.11.015_bib0046","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/annrheumdis-2019-216529","article-title":"Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR\/EULAR Boolean criteria optimal?","volume":"79","author":"Studenic","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ero.2025.11.015_bib0047","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ero.2025.11.015_bib0048","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/03009742.2014.992949","article-title":"Efficacy and safety of biological agents in adult-onset Still's disease","volume":"44","author":"Cavalli","year":"2015","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2025.11.015_bib0049","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MD.0000000000000021","article-title":"Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients","volume":"93","author":"Gerfaud-Valentin","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.ero.2025.11.015_bib0050","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003578","article-title":"Still's disease continuum from childhood to elderly: data from the international AIDA Network Still's disease registry","volume":"9","author":"Vitale","year":"2023","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.ero.2025.11.015_bib0051","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/rheumatology\/keac027","article-title":"Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease","volume":"61","author":"Ruscitti","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.ero.2025.11.015_bib0052","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1136\/ard-2024-225853","article-title":"Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR\/PReS recommendations for the diagnosis and management of Still's disease","volume":"83","author":"De Matteis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.11.015_bib0053","article-title":"Clinical practice guidelines we can trust","year":"2011"},{"issue":"7182","key":"10.1016\/j.ero.2025.11.015_bib0054","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/bmj.318.7182.527","article-title":"Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines","volume":"318","author":"Woolf","year":"1999","journal-title":"BMJ"},{"issue":"1-2","key":"10.1016\/j.ero.2025.11.015_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14712598.2024.2307340","article-title":"The latest advances in the use of biological DMARDs to treat Still's disease","volume":"24","author":"Di Cola","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ero.2025.11.015_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152139","article-title":"Systematic review on the use of biologics in adult-onset still's disease","volume":"58","author":"Fautrel","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ero.2025.11.015_bib0057","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1136\/annrheumdis-2020-218032","article-title":"Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease","volume":"81","author":"Ruscitti","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ero.2025.11.015_bib0058","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41584-020-00543-5","article-title":"Why remission is not enough: underlying disease mechanisms in RA that prevent cure","volume":"17","author":"Schett","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2025.11.015_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105418","article-title":"Sustained DMARD-free remission in rheumatoid arthritis - about concepts and moving towards practice","volume":"89","author":"Verstappen","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ero.2025.11.015_bib0060","doi-asserted-by":"crossref","unstructured":"Ruscitti P, Feist E, Canon-Garcia V, Rabijns H, Toennessen K, Bartlett C, et al. Burden of adult-onset Still's disease: a systematic review of health-related quality of life, utilities, costs and resource use. Semin Arthritis Rheum. 2023 Dec;63:152264. doi:10.1016\/j.semarthrit.2023.152264","DOI":"10.1016\/j.semarthrit.2023.152264"},{"issue":"2","key":"10.1016\/j.ero.2025.11.015_bib0061","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41584-023-01065-6","article-title":"Recent advances and evolving concepts in Still's disease","volume":"20","author":"Ruscitti","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.11.015_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105499","article-title":"Derivation and validation of adult Still Activity Score (SAS)","volume":"90","author":"Kalyoncu","year":"2023","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.ero.2025.11.015_bib0063","article-title":"Evaluation of performance of the still activity score for assessment of adult-onset Still's disease: comparative study with systemic feature score and modified Pouchot-Activity score","volume":"21","author":"Uslu","year":"2025","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.ero.2025.11.015_bib0064","article-title":"Clinical features and outcome measures across Still\u2019s disease (sJIA and AOSD) cohorts worldwide: a systematic literature review","author":"Balay-Dustrude","year":"2025","journal-title":"J Rheumatol"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125001156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125001156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:10:01Z","timestamp":1790716201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708125001156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S3050708125001156"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.015","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The EULAR points to consider regarding the development of criteria for the assessment of the disease activity in adult-onset Still\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100088"}}